{
      "Rank": 358,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.\n\nPatients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.\n\nMSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.",
            "Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.\n\nIsotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal stem cells",
            "Other: Isotonic solution"
      ],
      "ArmGroupLabel": [
            "Mensenchymal Stem Cells",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01045382"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning.\n\nCo-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, it has been shown that infusion of third party MSC in HSC transplantation could be successfully used as treatment for grade II-IV steroid-refractory acute graft versus host disease.\n\nOne hundred and twenty patients with HLA-mismatched donors will be included over 6 years at multiple centers across Belgium through the transplant committee of the Belgian Hematological Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of the patient will not differ from that of routine NM-HCT."
      ],
      "BriefTitle": [
            "MSC and HSC Coinfusion in Mismatched Minitransplants"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "AZ Sint-Jan AV",
            "Ziekenhuis Netwerk Antwerpen (ZNA)",
            "Jules Bordet Institute",
            "Universiteit Antwerpen",
            "AZ-VUB",
            "Cliniques universitaires Saint-Luc- Universit\u00e9 Catholique de Louvain",
            "University Hospital, Ghent"
      ],
      "CompletionDate": [
            "August 2021"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Leukemia, Myeloid, Acute",
            "Leukemia, Lymphoblastic, Acute",
            "Leukemia, Myelocytic, Chronic",
            "Myeloproliferative Disorders",
            "Myelodysplastic Syndromes",
            "Multiple Myeloma",
            "Leukemia, Lymphocytic, Chronic",
            "Hodgkin's Disease",
            "Lymphoma, Non-Hodgkin"
      ],
      "ConditionAncestorId": [
            "D000009370",
            "D000009369",
            "D000054219",
            "D000020141",
            "D000014652",
            "D000002318",
            "D000010265",
            "D000001796",
            "D000006402",
            "D000006474",
            "D000008232",
            "D000007160",
            "D000007154",
            "D000001855",
            "D000008223",
            "D000008206",
            "D000015448"
      ],
      "ConditionAncestorTerm": [
            "Neoplasms by Histologic Type",
            "Neoplasms",
            "Neoplasms, Plasma Cell",
            "Hemostatic Disorders",
            "Vascular Diseases",
            "Cardiovascular Diseases",
            "Paraproteinemias",
            "Blood Protein Disorders",
            "Hematologic Diseases",
            "Hemorrhagic Disorders",
            "Lymphoproliferative Disorders",
            "Immunoproliferative Disorders",
            "Immune System Diseases",
            "Bone Marrow Diseases",
            "Lymphoma",
            "Lymphatic Diseases",
            "Leukemia, B-Cell"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "BC14",
            "BC15",
            "BC20",
            "All",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "Heart and Blood Diseases",
            "Blood and Lymph Conditions",
            "Immune System Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Multiple Myeloma",
            "Leukemia",
            "Leukemia, Myeloid",
            "Leukemia, Myeloid, Acute",
            "Myelodysplastic Syndrome",
            "Hodgkin's Disease",
            "Lymphoma, Non-Hodgkin",
            "Myeloproliferative Disorders",
            "Leukemia, Lymphocytic",
            "Leukemia, Lymphocytic, Chronic",
            "Leukemia, Lymphoblastic, Acute",
            "Leukemia, Myelocytic, Chronic",
            "Multiple Myeloma",
            "Leukemia, Lymphocytic, Chronic",
            "Myelodysplastic Syndrome",
            "Myeloproliferative Disorders",
            "Leukemia, Lymphoblastic, Acute",
            "Leukemia, Lymphoblastic, Acute"
      ],
      "ConditionBrowseLeafId": [
            "M11210",
            "M26741",
            "M10097",
            "M15507",
            "M10107",
            "M17279",
            "M10372",
            "M13316",
            "M11297",
            "M8903",
            "M10374",
            "M11301",
            "M10103",
            "M17268",
            "M26738",
            "M17275",
            "M11467",
            "M21130",
            "M4211",
            "M16552",
            "M12330",
            "M4229",
            "M8642",
            "M8712",
            "M10377",
            "M9358",
            "M9352",
            "M4286",
            "M10355",
            "M17267",
            "T3947",
            "T1308",
            "T3543",
            "T3993",
            "T1303",
            "T2817",
            "T1311",
            "T170",
            "T175",
            "T3533"
      ],
      "ConditionBrowseLeafName": [
            "Multiple Myeloma",
            "Neoplasms, Plasma Cell",
            "Leukemia",
            "Syndrome",
            "Leukemia, Myeloid",
            "Leukemia, Myeloid, Acute",
            "Lymphoma",
            "Preleukemia",
            "Myelodysplastic Syndromes",
            "Hodgkin Disease",
            "Lymphoma, Non-Hodgkin",
            "Myeloproliferative Disorders",
            "Leukemia, Lymphoid",
            "Leukemia, Lymphocytic, Chronic, B-Cell",
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
            "Neoplasms by Histologic Type",
            "Hemostatic Disorders",
            "Blood Coagulation Disorders",
            "Vascular Diseases",
            "Paraproteinemias",
            "Blood Protein Disorders",
            "Hematologic Diseases",
            "Hemorrhagic Disorders",
            "Lymphoproliferative Disorders",
            "Immunoproliferative Disorders",
            "Immune System Diseases",
            "Bone Marrow Diseases",
            "Lymphatic Diseases",
            "Leukemia, B-Cell",
            "Multiple Myeloma",
            "Chronic Lymphocytic Leukemia",
            "Lymphosarcoma",
            "Myelodysplastic Syndromes",
            "Chronic Graft Versus Host Disease",
            "Hodgkin Lymphoma",
            "Chronic Myeloproliferative Disorders",
            "Acute Graft Versus Host Disease",
            "Acute Lymphoblastic Leukemia",
            "Lymphoblastic Lymphoma"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "low",
            "high",
            "high",
            "low",
            "low",
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low",
            "high",
            "low",
            "low",
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000007938",
            "D000009101",
            "D000006689",
            "D000008228",
            "D000007951",
            "D000015470",
            "D000007945",
            "D000015451",
            "D000054198",
            "D000015464",
            "D000009190",
            "D000009196"
      ],
      "ConditionMeshTerm": [
            "Leukemia",
            "Multiple Myeloma",
            "Hodgkin Disease",
            "Lymphoma, Non-Hodgkin",
            "Leukemia, Myeloid",
            "Leukemia, Myeloid, Acute",
            "Leukemia, Lymphoid",
            "Leukemia, Lymphocytic, Chronic, B-Cell",
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
            "Myelodysplastic Syndromes",
            "Myeloproliferative Disorders"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nTheoretical indication for a standard allo-transplant, but not feasible because: Age > 55 yrs. Unacceptable end organ performance. Patient's refusal.\nIndication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.\nMale or female; fertile female patients must use a reliable contraception method\nAge \u2264 75 year old\nInformed consent given by patient or his/her guardian if of minor age.\n\nOne or two HLA mismatches with PBSC:\n\nOne antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1\nTwo allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1\nOne antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.\nOne antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1\nPatients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 can also be included in the protocol.\n\nHematological malignancies confirmed histologically and not rapidly progressing:\n\nAML in complete remission\nALL in complete remission\nCML unresponsive/intolerant to Imatinib but not in blast crisis\nOther myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis\nMDS with <5% blasts\nMultiple myeloma not rapidly progressing\nCLL\nNon-Hodgkin's lymphoma (aggressive NHL should be chemosensitive)\nHodgkin's disease\n\nExclusion Criteria:\n\nAny condition not fulfilling inclusion criteria\nHIV positive\n\nTerminal organ failure, except for renal failure (dialysis acceptable)\n\nCardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia; uncontrolled hypertension\nPulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen\nHepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease\nUncontrolled infection, arrhythmia or hypertension\nPrevious radiation therapy precluding the use of 2 Gy TBI\n10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC."
      ],
      "EnrollmentCount": [
            "39"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mensenchymal Stem Cells",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "All",
            "PhSol"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M283219",
            "M21013",
            "M225481"
      ],
      "InterventionBrowseLeafName": [
            "Fludarabine",
            "Pharmaceutical Solutions",
            "Fludarabine phosphate"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Mesenchymal stem cell injection",
            "Isotonic solution injection"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal stem cells",
            "Isotonic solution"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "HSC transplantation",
            "HLA-mismatched",
            "Mesenchymal stem cells",
            "GVHD",
            "co-infusion"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 8, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "August 31, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "University of Liege"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Edeghem",
            "Brussels",
            "Leuven",
            "Gent",
            "Brugge",
            "Yvoir",
            "Antwerpen",
            "Brussels",
            "Brussels",
            "Li\u00e8ge"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium",
            "Belgium"
      ],
      "LocationFacility": [
            "UZA",
            "St-Luc UCL",
            "AZ Gasthuisberg Leuven",
            "UZ Gent",
            "AZ St-Jan",
            "Cliniques Universitaires Mont-Godinne",
            "H\u00f4pital Stuyvenberg",
            "Bordet Institute",
            "Vrije Universiteit Brussel",
            "CHU-ULg"
      ],
      "LocationState": [
            "Antwerpen",
            "Brabant",
            "Flamish Brabant",
            "Flanders Ost",
            "Flanders West",
            "Namur"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "2650",
            "1200",
            "3000",
            "9000",
            "8000",
            "5530",
            "2060",
            "1000",
            "1050",
            "4000"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Liege"
      ],
      "OrgStudyId": [
            "TJB0909"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "CHU-ULg",
            "CHU-ULg",
            "CHU-ULg",
            "AZ Brugge",
            "ZNA Antwerpen",
            "Bordet Institute, Brussels",
            "Bordet Institute, Brussels",
            "UZA Antwerpen",
            "CHU-ULg",
            "CHU-ULg",
            "KUL, Leuven",
            "AZ VUB, Brussels",
            "UCL St. LUC, Brussels",
            "UZG Gent",
            "Cliiques Universitaire Mont-Godinne, Yvoir",
            "UZA, Antwerpen",
            "Cliniques Universitaires, Mont-Godinne"
      ],
      "OverallOfficialName": [
            "Yves Beguin, MD, PhD",
            "Fr\u00e9d\u00e9ric Baron, MD, PhD",
            "Evelyne Willems, MD",
            "Dominik Selleslag, MD, PhD",
            "Pierre Zach\u00e9e, MD, PhD",
            "Philippe Lewalle, MD, PhD",
            "Dominique Bron, MD, PhD",
            "Wilfried Schroyens, MD, PhD",
            "Chantal Lechanteur, PhD",
            "Etienne Baudoux, MD",
            "Johan Maertens, MD",
            "Rik Schots, MD, PhD",
            "Augustin Ferrant, MD, PhD",
            "Lucien Noens, MD, PhD",
            "Chantal Doyen, MD, PhD",
            "Tessa Kerre, MD, PhD",
            "Carlos Graux, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Study Chair",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Terminated"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "August 2021"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "One-year overall survival in the 2 arms."
      ],
      "PrimaryOutcomeTimeFrame": [
            "One year"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of Liege"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Yves Beguin"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Prof"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Incidence of grade II-IV and grade III-IV acute GVDH",
            "Number of absolute donor T cells after HCT in each arm",
            "Cumulative incidence of non-relapse mortality",
            "Incidence of extensive chronic GVHD in each arm",
            "Incidence of graft rejection in each arm.",
            "Quality and timing of immunologic reconstitution in each arm.",
            "Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC",
            "Proportion of patients with measurable disease at HCT who achieve a complete response in each arm.",
            "Cumulative incidence of relapse",
            "Incidence of progression-free survival",
            "Incidence of infections"
      ],
      "SecondaryOutcomeTimeFrame": [
            "100 days",
            "28",
            "100, 365 and 730 days",
            "365 days",
            "365 days",
            "100, 365 and 730 days",
            "40 days",
            "100, 365 and 730 days",
            "365 and 730 days",
            "365 and 730 days",
            "100 days"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "July 2010"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "August 2021"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 11, 2010"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "January 8, 2010"
      ],
      "StudyFirstSubmitQCDate": [
            "January 8, 2010"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": [
            "recruitment too slow"
      ]
}